乳腺癌患者中断辅助内分泌治疗尝试妊娠中的生育力保存与辅助生殖技术
POSITIVE研究为国际单臂前瞻性试验,518例早期激素受体阳性乳腺癌患者暂时中断辅助内分泌治疗尝试妊娠。中位随访41个月,74%可评估患者报告至少一次妊娠;诊断时卵巢刺激行生育力保存未增加短期乳腺癌事件风险。
要点
- 入组时273例(53%)报告闭经,其中94%在12个月内恢复月经。
- 可评估妊娠的497例中368例(74%)报告至少一次妊娠,年轻是妊娠时间更短的主要因素。
- 诊断时行卵巢刺激生育力保存者3年无乳腺癌事件累积发生率9.7%,未行者8.7%,短期无显著差异。
核心结论
- POSITIVE研究中,使用卵巢刺激进行生育力保存与短期癌症预后不良影响无关。
- 在行胚胎/卵母细胞冷冻保存并随后进行胚胎移植的患者中,妊娠率最高。
研究设计与样本
- POSITIVE为国际、单臂、前瞻性试验,共纳入518例暂时中断辅助内分泌治疗以尝试妊娠的早期激素受体阳性乳腺癌女性。
- 中位随访41个月。
主要发现
- 入组时273例(53%)报告闭经,其中94%在12个月内恢复月经。
- 可评估妊娠的497例患者中,368例(74%)报告至少一次妊娠。
- 年龄<35岁、35-39岁和40-42岁患者1年累积妊娠发生率分别为63.5%、54.3%和37.7%。
- 179例(36%)在诊断时行胚胎/卵母细胞冷冻保存,其中68例报告入组后行胚胎移植。
- 冷冻胚胎移植是唯一与更高妊娠机会相关的辅助生殖技术(比值比2.41,95%CI 1.75至4.95)。
关键数值与推荐
- 年龄<35岁、35-39岁和40-42岁患者1年累积妊娠发生率分别为63.5%、54.3%和37.7%。
- 冷冻胚胎移植与更高妊娠机会相关(比值比2.41,95%CI 1.75至4.95)。
- 诊断时行卵巢刺激冷冻保存者3年无乳腺癌事件累积发生率为9.7%(95%CI 6.0至15.4),未行者8.7%(95%CI 6.0至12.5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We investigated time to pregnancy, efficacy and safety of fertility preservation, and assisted reproductive technologies (ARTs) in women with early hormone receptor-positive breast cancer (BC) desiring future pregnancy. PATIENTS AND METHODS: POSITIVE is an international, single-arm, prospective trial, in which 518 women temporarily interrupted adjuvant endocrine therapy to attempt pregnancy. We evaluated menstruation recovery and factors associated with time to pregnancy and investigated if ART use was associated with achieving pregnancy. The cumulative incidence of BC-free interval (BCFI) events was estimated according to the use of ovarian stimulation at diagnosis. The median follow-up was 41 months. RESULTS: Two hundred seventy-three patients (53%) reported amenorrhea at enrollment, of whom 94% resumed menses within 12 months. Among 497 patients evaluable for pregnancy, 368 (74%) reported at least one pregnancy. Young age was the main factor associated with shorter time to pregnancy with cumulative incidences of pregnancy by 1 year of 63.5%, 54.3%, and 37.7% for patients age <35, 35-39, and 40-42 years, respectively. One hundred and seventy-nine patients (36%) had embryo/oocyte cryopreservation at diagnosis, of whom 68 reported embryo transfer after enrollment. Cryopreserved embryo transfer was the only ART associated with higher chance of pregnancy (odds ratio, 2.41 [95% CI, 1.75 to 4.95]). The cumulative incidence of BCFI events at 3 years was similar for women who underwent ovarian stimulation for cryopreservation at diagnosis, 9.7% (95% CI, 6.0 to 15.4), compared with those who did not, 8.7% (95% CI, 6.0 to 12.5). CONCLUSION: In POSITIVE, fertility preservation using ovarian stimulation was not associated with short-term detrimental impact on cancer prognosis. Pregnancy rates were highest among those who underwent embryo/oocyte cryopreservation followed by embryo transfer.
引用
- Azim HA, Niman SM, Partridge AH, et al. Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy. J Clin Oncol. 2024. PMID: 38810178. doi:10.1200/JCO.23.02292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。